Deltoid Injection Volume for 40mg/ml Kenalog
For deltoid injections with 40mg/ml Kenalog, inject 0.25-1 mL (10-40 mg), with careful attention to avoid surrounding tissue infiltration which can cause atrophy.
Dosing Based on FDA Label and Clinical Context
The FDA label for Kenalog-40 provides specific guidance for local injections 1:
- Smaller joints/areas: 2.5-5 mg (0.06-0.125 mL of 40mg/ml)
- Larger joints/areas: 5-15 mg (0.125-0.375 mL of 40mg/ml)
- Adults, larger areas: Up to 40 mg (1 mL of 40mg/ml) have been sufficient
The deltoid region requires special caution - the FDA label explicitly warns: "Care should be taken with this kind of injection, particularly in the deltoid region, to avoid injecting the suspension into the tissues surrounding the site, since this may lead to tissue atrophy" 1.
Practical Dosing Algorithm
For deltoid injections, consider:
Subacromial/shoulder joint injections: Recent evidence supports 1 mL (40 mg) as effective 2, 3, 4
- This is the most common deltoid-region indication
- Both 10 mg and 40 mg show efficacy, but 40 mg demonstrates superior symptom relief in some studies 5
Smaller lesions or superficial injections: 0.25-0.5 mL (10-20 mg)
- Lower doses reduce atrophy risk
- Particularly important when injecting near subcutaneous tissue
Acne lesions (if applicable): Use diluted concentrations, not 40mg/ml
- Guidelines recommend 10 mg/mL for nodular acne, diluted to 5 or 3.3 mg/mL 6
- The 40mg/ml concentration is reserved for hypertrophic scars and keloids
Critical Safety Considerations
Avoid these common pitfalls:
- Subcutaneous infiltration: The primary risk in the deltoid is injecting into surrounding fat/tissue rather than the intended target (joint, bursa, or deep tissue), causing visible atrophy, pigmentary changes, and telangiectasias 1
- Use proper needle length: Minimum 1½ inches for adults to reach appropriate depth 1
- Single injection technique: Inject without delay after drawing up to prevent settling in the syringe 1
Evidence Summary
Recent research shows that for shoulder injections, 40 mg (1 mL) is standard and effective 2, 3. One study found no additional benefit of high-volume dilution (10 mL total) versus low-volume (3 mL total) when using 40 mg triamcinolone 2. However, for knee osteoarthritis, 10 mg was non-inferior to 40 mg 7, and for adhesive capsulitis, one older study suggested 40 mg provided superior relief compared to 10 mg 5, though a more recent study found no difference between 20 mg and 40 mg 4.
The most conservative approach for deltoid-region injections is 0.5-1 mL (20-40 mg) with meticulous technique to ensure proper depth and avoid surrounding tissue infiltration.